Results 41 to 50 of about 47,954 (202)

Development of multiple myeloma in a patient with chronic hepatitis C: A case report and review of the literature [PDF]

, 2006
An association between chronic hepatitis C virus (HCV) infection and essential mixed cryoglobulinaemia and non-Hodgkin lymphoma (NHL) has been suggested. However, a causative role of HCV in these conditions has not been established.
Lakatos, Péter László, Horányi, Margit, Abonyi, Margit E., Fischer, Simon, Fekete, Sándor   +4 more
core   +1 more source

Crystallization Selectivity of Ribavirin Solution and Amorphous Phase

Molecules, 2023
Crystallization selectivity is an important principle in polymorph control. Ribavirin Form I, Form II, DMSO solvate, and amorphous ribavirin are prepared, and the short-range order similarities between these solid forms and ribavirin aqueous solution and
Fuying Li, Shiying Chen, Haoxin Hu, Chengfeng Liang, Shiyu Sun, Can Jin, Fenghua Chen   +6 more
doaj   +1 more source

Absence of progressive liver disease after treatment in children with chronic hepatitis C: A nationwide registry study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives In adults with chronic hepatitis C (CHC) and advanced fibrosis, hepatocellular carcinoma (HCC) surveillance is recommended after achieving a sustained virologic response (SVR). However, post‐SVR surveillance strategies for children remain unclear. The aim of this study was to assess the durability of SVR and determine an appropriate
Hitoshi Tajiri, Mitsuyoshi Suzuki, Yuri Etani, Yoshinori Ito, Koichi Ito, Tomoya Fukuoka, Tatsuki Mizuochi   +6 more
wiley   +1 more source

Impact of Genetic Variants in Inosine Triphosphate Pyrophosphatase and Interferon-λ4 on Natural History, Treatment Response and Ribavirin Pharmacology in Hepatitis C Virus Infection [PDF]

, 2020
Hepatitis C virus (HCV) impacts on global health with around 70 million chronically infected worldwide. The infection increases the risk of cirrhosis and primary liver cancer.
Waldenström, Jesper
core   +1 more source

Ribavirin and its analogs: Сan you teach an old dog new tricks?

Тонкие химические технологии, 2019
The review article focuses on the current state of synthetic and biological studies of ribavirin analogs. Ribavirin is a broad-spectrum nucleoside antiviral drug with a 50-year long history of research and application, but its mechanism of action still ...
M. V. Chudinov
doaj   +1 more source

Efficacy and Adverse Effects of Sofosbuvir-Based Therapies (Double and Triple Regimens) in Chronic HCV Patients [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases, 2017
Background and study aim: Egypt has the highest prevalence of hepatitis C virus in the world and it is about14.7 %. Until 2012, the combination of pegylated interferon-α and ribavirin was the standard of care in CHC.
Amal Jouda, Hosam Dawod, Nahla Elgammal
doaj   +1 more source

Enterovirus infections in children

Pediatric Investigation, EarlyView.
Enteroviruses (EVs) are major pathogens causing a wide spectrum of diseases in children worldwide. This review summarizes the epidemiology, virology, viral replication, and virus‐host interactions of EVs. It also highlights current advances in clinical diagnosis, antiviral therapies, and vaccine development, providing insights into future strategies ...
Xiangpeng Chen, Lingyun Guo, Xiaobo Lei, Linqing Zhao, Mingyan Hei, Jun Shen, Ju Yin, Fei Li, Jikui Deng, Gang Liu, Yong Zhang, Zhengde Xie   +11 more
wiley   +1 more source

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial

Annals of Hepatology, 2003
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection.
Francisco Bosques-Padilla, MD, Rafael Trejo-Estrada, MD, Octaivio Campollo-Rivas, MD, Carlos Cortez-HernÁndez, MD, Margarita Dehesa-Violante, MD, Héctor Maldonado-Garza, MD, Raúl Pérez-Gómez, MD, Armando Cabrera-Valdespino, MD   +7 more
doaj   +1 more source

Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria

BMJ Open, 2020
Introduction Lassa fever (LF) is a severe and often fatal systemic disease in humans and affects a large number of countries in West Africa. Treatment options are limited to supportive care and the broad-spectrum antiviral agent ribavirin.
Michael Ramharter, Osahogie Edeawe, Peter Akhideno, Gloria Eifediyi, Till F Omansen, Christine Wagner, Francisca Sarpong, Till Koch, Sebastian Wicha, Florian Kurth, Sophie Duraffour, Lisa Oestereich, Meike Pahlmann, Sylvanus Okogbenin, Ephraim Ogbaini-Emovon, Stephan Günther, Mirjam Groger   +16 more
doaj   +1 more source

Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.

PLoS Neglected Tropical Diseases, 2022
Ribavirin is currently the standard of care for treating Lassa fever. However, the human clinical trial data supporting its use suffer from several serious flaws that render the results and conclusions unreliable.
Alex P Salam, Alexandre Duvignaud, Marie Jaspard, Denis Malvy, Miles Carroll, Joel Tarning, Piero L Olliaro, Peter W Horby   +7 more
doaj   +1 more source